Literature DB >> 29026535

Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in the intensive care unit.

Xia Zheng1, Jian-Feng Wang2, Wang-Lan Xu3, Jun Xu1, Juan Hu1.   

Abstract

BACKGROUND: To analyze the clinical characteristics and outcomes of carbapenem-resistant Klebsiella pneumoniae (CRKp) and carbapenem-susceptible K. pneumoniae (CSKp) bloodstream infections (BSIs), and to study the risk factors for development of CRKp BSI and K. pneumoniae BSI-related mortality.
METHODS: A retrospective case control study of patients with K. pneumoniae BSI was conducted in the intensive care unit of the First Affiliated Hospital, Medical of College, Zhejiang University from January 2013 to December 2014. Carbapenem resistance was defined in accordance with the Clinical and Laboratory Standards Institute 2016 guidelines. Risk factors for the development of CRKp BSI and risk factors for mortality due to K. pneumoniae BSI were assessed. Virulence genes were detected by polymerase chain reaction assay.
RESULTS: In total, 48 patients were enrolled in the study, including 31 (65%) patients with CRKp BSI and 17 (35%) patients with CSKp BSI. CSKp infection was associated with more severe clinical symptoms, particularly a higher serum creatinine level (165.06 ± 127.01 in the CSKp group vs. 93.77 ± 84.35 μmol/L in the CRKp group, p = 0.039), but there was no significant difference in prognosis between the CSKp and CRKp groups. On multivariate analysis, indwelling central venous catheter (p = 0.045) was the only factor independently associated with CRKp bacteremia. However, the mortality of K. pneumoniae BSI patients was not correlated with carbapenem resistance. In addition, the isolates had diverse clonality and different origins. The frequency of detection of the allS and magA virulence genes was higher in the CSKp group than in the CRKp group (alls p = 0.04; magA p = 0.047).
CONCLUSIONS: Patients in the CSKp group experienced more severe clinical symptoms, although mortality did not differ significantly between the CRKp and CSKp groups. An indwelling central venous catheter was the only factor independently associated with CRKp BSI. The mortality of patients with K. pneumoniae BSI was not associated with carbapenem resistance. The frequency of virulence genes was higher in the CSKp group than in the CRKp group.

Entities:  

Year:  2017        PMID: 29026535      PMCID: PMC5625719          DOI: 10.1186/s13756-017-0256-2

Source DB:  PubMed          Journal:  Antimicrob Resist Infect Control        ISSN: 2047-2994            Impact factor:   4.887


Background

Klebsiella pneumoniae, a member of the family Enterobacteriaceae, is a causative organism of various infections, including serious community-onset infections, such as necrotizing pneumonia, pyogenic liver abscesses, and endogenous endophthalmitis [1, 2]; and nosocomial infections, particularly urinary tract infections (UTIs), respiratory tract infections, and bloodstream infections (BSIs) [1, 3, 4]. Due to abuse of antimicrobial agents in developing countries, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) is of considerable concern. K. pneumoniae is the most prevalent Enterobacteriaceae species, accounting for 71.9% of 242 CRE strains in a retrospective study conducted in a tertiary hospital in Hangzhou, China [5]. Surveillance of antibiotic resistance by the China CHINET showed that 2.9% and 2.8% of Klebsiella spp. were resistant to imipenem and meropenem, respectively, in 2005 compared to 10.5% and 13.4%, respectively, in 2014 [6]. The production of carbapenemases (e.g., KPC, NDM, VIM, OXA-48-like) is the most common mechanism of resistance among K. pneumoniae isolates. Other mechanisms include alterations in outer membrane permeability, mediated by loss of porins and the upregulation of efflux systems [7]. The mortality rate of carbapenem-resistant Klebsiella pneumoniae (CRKp) infections in North America, South America, Europe, and Asia is reportedly 33.24%, 46.71%, 50.06%, and 44.82%, respectively [8]. Similarly, a study done in Shanghai, China showed that the 28-day mortality and in-hospital mortality rates of CRKp BSI patients were significantly higher than those of patients with carbapenem-susceptible K. pneumoniae (CSKp) BSIs (33.3% vs. 16%, p = 0.04; 42.4% vs. 24.6%, p = 0.005, respectively) [9]. Although CRKp is reportedly associated with prolonged hospitalization and mortality [8, 10–12] because such patients typically receive inappropriate empiric therapy, other studies found no such relationship [13-15]. There are various risk factors for CRKp BSI. A study conducted in a teaching hospital in Shanghai, China suggested that skin and soft tissue infection (odds ratio [OR] 26.63 and ICU-acquired infection (OR 5.82) was a risk factor for CRKp BSI [9]. multisite colonization (hazard ratio [HR] 13.73), ICU stay (HR 3.14) and previous BSI (HR 6.62) was associated with the development of CRKp BSI in colonized patients [16]. Primary liver disease and hepatitis C virus infection or hepatocellular cancer were significantly associated with development of CRKp in intensive care unit (ICU) patients after orthotopic liver transplantation [17]. Even no exposure independently predicted CRKp BSI in carriers of CRKp [18]. Similarly, several factors are reportedly associated with mortality related to K. pneumoniae BSI. The lung as the probable source of infection (OR 4.23) and a high Sequential Organ Failure Assessment (SOFA) score (OR 1.40) were strong prognostic factors for crude 28-day K. pneumoniae BSI mortality in a teaching hospital in Shanghai, China [9]. Septic shock (HR 3.86), acute respiratory failure (HR 2.32), inadequate initial antimicrobial therapy (HR 1.87) and carbapenem resistance by K. pneumoniae isolates (HR 1.85) were independently associated with mortality in onco-hematological patients [19]. In a univariate analysis, Acute Physiology and Chronic Health Evaluation (APACHE II) score, SOFA score, and CRKp BSI were predictive of ICU mortality after orthotopic liver transplantation [17]. It is generally accepted that CRKp BSIs are associated with high mortality, mostly because of the paucity of antimicrobials active against CRKp and the multiple comorbidities of patients [20]. Severe infection causes organ dysfunction and/or failure via complex mechanisms, including pathogenic microorganisms, an excessive inflammatory response, and immune dysfunction. However, antimicrobial resistance does not always lead to organ dysfunction and/or failure [21]. The immune system plays an important role in disease manifestations, with multiple contributing factors, some of which may not be accounted for by routinely collected data. At present, whether the systemic manifestations of infection and frequency of bacterial virulence genes differ between CRKp and CSKp BSI patients is unclear. Therefore, the objective of our study was to compare the prognosis and clinical characteristics of patients with CRKp and CSKp infections in the ICU, identify risk factors for the development of CRKp BSI and mortality of K. pneumoniae BSI, and assess the frequency of bacterial virulence genes in patients with CRKp and CSKp BSI.

Methods

Study design and patients

This retrospective case-control study was conducted at the First Affiliated Hospital of the Medical College, Zhejiang University, a 2500-bed tertiary-care teaching hospital, and included all adult patients with BSI caused by K. pneumoniae and hospitalized in the 30-bed medical ICU from January 1, 2013 to December 31, 2014. The patients were identified using the records of the clinical microbiology laboratory. All patients with a positive blood culture for K. pneumoniae was included in the study. Infective symptoms and signs were compatible with systemic inflammatory response syndrome (SIRS; i.e., fever or hypothermia, respiratory rate > 20 breaths per minute, tachycardia >90 beats/min, and white blood cell count >11,000 ml or <4000/ml, using the 1999 criteria). If more than one episode occurred in the same patient, only the first episode was included in the study [22]. Cases with incomplete medical records were excluded from the study. From 2013, the identification and antimicrobial susceptibility testing of all blood K. pneumoniae isolates were performed using Vitek 2 panels (bioMerieux, France); isolates were stored at −80 °C [23]. Reserved strains were retrospectively tested for the presence of specific virulence genes. The patients were divided into the CRKp and CSKp groups. Carbapenem resistance was defined as a minimum inhibitory concentration of ≥4 mg/L for meropenem or imipenem or ≥2 mg/L for ertapenem; other strains were defined as carbapenem-susceptible. Data interpretation was performed in accordance with the Clinical and Laboratory Standards Institute (CLSI) 2016 guidelines. To identify risk factors for the development of CRKp BSI and m related ortality, the following data were recorded: demographics (sex, age), comorbidities, history of surgery, hospital or ICU admission in the last 30 days, use of steroids or immune modulators, antibiotic exposure history, and indwelling prosthetic material. In addition, for assessment of severe infection, APACHE II scores, liver function, kidney function, and inflammatory markers, at admission and at the time of positive blood culture, were recorded [17, 19]. The primary outcomes were crude survival rates at 7, 14, and 28 days. Secondary outcomes were current ICU stay duration, bacterial clearance rate, and duration of mechanical ventilation [24].

Multilocus sequence typing and pulsed-field gel electrophoresis

According to the multilocus sequence typing (MLST) scheme of K. pneumonia, seven conserved housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB, and tonB) were amplified and sequenced [25]. Pulsed-field gel electrophoresis (PFGE) was performed using XbaI (Dalian Takara Bio Inc., China), as described previously. To identify isolates associated with outbreaks, PFGE band patterns were interpreted according to the criteria proposed by Tenover et al. [26, 27].

Detection of virulence genes by polymerase chain reaction

The K1, K2, K5, K20, K54, and K57 capsular serotypes were detected by polymerase chain reaction (PCR), as described previously. Virulence genes (magA, rmpA, rmpA2, and allS) were detected by PCR using primers, as described previously. PCR products were interpreted and sequenced [23].

Statistical analysis

Statistical analyses were performed using SPSS software (ver. 18.0; SPSS Inc., USA). Continuous variables are presented as means ± SD and were evaluated by Student’s t-test or the Mann-Whitney U test, as appropriate. A chi-squared test or Fisher’s exact test was used for categorical variables, and multivariate analyses were performed using logistic regression models to identify independent risk factors for the outcome variables. All biologically plausible variables significant at p < 0.10 in univariate analysis were entered into a multivariate forward logistic regression analysis. A p value <0.05 was considered to indicate statistical significance.

Results

Demographics of the study population

Between January 1, 2013 and December 31, 2014, 48 patients had at least one episode of K. pneumoniae BSI in the ICU of our hospital. Thirty-three bloodstream isolates were included in this study; the others were excluded due to incomplete clinical information. The mean age in the CRKp and CSKp groups was 57.61 ± 14.78 and 62.71 ± 16.34 years, respectively (p = 0.306). Male patients accounted for 79% of the patients (56% in the CRKp group and 23% in the CSKp group, p = 0.502). To assess the frequency of bacterial virulence genes, 33 isolates (21 resistant and 12 susceptible) were obtained from 33 patients (17 and 4 male patients from the CRKp and CSKp groups, respectively [p = 0.357]). The mean age of these patients was 58.14 ± 15.16 and 65.58 ± 15.57 years, respectively (p = 0.190).

Clinical symptoms and prognostic factors of K. pneumoniae BSI

APACHEII score, peripheral blood leukocyte count, and C-reactive protein level were higher in the CSKp group than in the CRKp group at the time of bacteremia, albeit not significantly so. Many indexes showed the deteriorative tendencies in CSKp, including coagulation function, liver and kidney function, however only the static difference occurred in serum creatinine level (165.06 ± 127.01 in the CSKp group vs. 93.77 ± 84.35 μmol/L in the CRKp group, p = 0.039) (Table 1).
Table 1

Clinical symptoms of K. pneumoniae BSI

VariableCSKp (n = 17)CRKp (n = 31) P
APACHEII score(mean ± SD)18.18 ± 7.4815.03 ± 6.380.089
WBC 10E9/L (mean ± SD)14.24 ± 13.6313.99 ± 9.660.497
leukocytes count (mean ± SD)81.20 ± 14.6088.02 ± 7.950.180
CRP(mg/l)(mean ± SD)162.49 ± 118.07113.74 ± 79.630.191
ALT (mean ± SD)152.88 ± 399.2349.84 ± 50.050.359
AST (mean ± SD)490.82 ± 1655.6449.63 ± 48.540.088
Total bilirubin (mean ± SD)73.06 ± 142.1762.68 ± 128.660.754
Direct bilirubin (mean ± SD)43.29 ± 83.5839.48 ± 86.630.779
PT (s) (mean ± SD)17.71 ± 10.5415.05 ± 5.270.439
Creatinine (mean ± SD)165.06 ± 127.0193.77 ± 84.350.039
Urea nitrogen (mean ± SD)14.42 ± 9.8814.40 ± 10.050.931

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, WBC white blood cell, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, PT prothrombin time

Clinical symptoms of K. pneumoniae BSI Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, WBC white blood cell, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, PT prothrombin time The prognostic factors of the CRKp and CSKp BSI patients are presented in Table 2. The duration of mechanical ventilation of the CRKp and CSKp groups was 18.50 ± 31.91 and 28.72 ± 31.06 days, respectively (p = 0.127). The current ICU stay duration was similar between the CRKp and CSKp groups (21.47 ± 33.67 vs. 31.74 ± 30.75 days, respectively [p = 0.073]). The bacterial clearance rate was 32% and 35% in the CRKp and CSKp groups, respectively (p = 0.718). The survival rate of the CRKp group was 74% at 7 days, 68% at 14 days, and 61% at 28 days, compared to 65% at 7 days, 59% at 14 days, and 47% at 28 days in the CSKp group (p = 0.489, 0.537, and 0.342, respectively).
Table 2

Clinical outcomes of K. pneumoniae BSI

VariableCSKp (n = 17)CRKp (n = 31) P
Duration of mechanical ventilation (mean ± SD)(d)18.50 ± 31.9128.72 ± 31.060.127
Current ICU stay21.47 ± 33.6731.74 ± 30.750.073
Bacterial clearance rate6(35%)10(32%)0.718
7-day survival rate11(65%)23(74%)0.489
14-day survival rate10(59%)21(68%)0.537
28-day survival rate8(47%)19(61%)0.342

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, ICU intensive care unit

Clinical outcomes of K. pneumoniae BSI Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, ICU intensive care unit

Risk factors for the development of CRKp BSI

In univariate analyses, development of CRKp BSI was significantly associated with central venous catheterization and an indwelling urinary catheter, but not with comorbidities (including diabetes mellitus, hypertension, coronary heart disease,chromic liver disease, chronic renal failure, solid organ tumor, history of surgery, prior healthcare-associated exposure, exposure to glucocorticoids and/or immunosuppressive drugs, trachea cannula or tracheotomy, an indwelling nasogastric tube, a drainage tube at multiple sites, and APACHE II score at admission). Hepatic and renal function at admission showed a trend towards being associated with the development of CRKp BSI. Although the majority of CRKp BSI patients had been exposed to antimicrobials before the positive culture, only exposure to tigecycline, imipenem and meropenem were included in the multivariate analysis of CRKp BSI (Table 3).
Table 3

Univariate analysis of risk factors for CRKp BSI

VariableCSKp (n = 17)CRKp (n = 31)Univariate analysis
Adjusted OR95% CI P-value
Sex (male, n)11(65%)27(87%)0.6110.144—2.5960.502
Age (y) (mean ± SD)62.71 ± 16.3457.61 ± 14.780.306
Co- morbidities
 Diabetes mellitus5 (29%)9 (29%)0.9820.268—3.6020.978
 Hypertension9 (53%)15 (48%)0.8330.255—2.7240.763
 Coronary heart disease1 (6%)3 (10%)1.7140.164—17.8861
 Chronic liver disease3(18%)6(19%)1.1200.242–5.1861
 Chronic renal failure2 (12%)4 (13%)1.1110.182—6.7960.909
 Solid organ tumor4 (24%)7 (23%)0.9480.233—3.8500.940
 HIV00NANANA
 Surgery in the past medical historya 3 (18%)5 (16%)0.8970.186—4.3220.893
 Prior healthcare-associated exposure7 (41%)9 (29%)0.5840.169—2.0170.393
Prior medicine exposure
 Glucocorticoid7 (41%)13 (42%)1.0320.311—3.4280.959
 Immunosuppressorb 1 (6%)2 (6%)1.1030.093—13.1351
Prior use of antimicrobials
 Penicillin3 (18%)10 (32%)2.1050.480—9.2370.318
 Second cephalosporin1 (6%)4 (13%)2.2400.228—22.0510.838
 extended-spectrum cephalosporins7 (41%)15 (48%)1.2240.351—4.2690.750
 Aminoglycosides1 (6%)3 (10%)1.6150.153—17.0161
 Quinolones1 (6%)3 (10%)1.6150.153—17.0161
 Tigecycline04 (13%)0.6250.492—0.7950.613
 Imipenem1 (6%)11(39%)8.5560.984—74.408 0.064
 Meropenem1 (6%)12 (39%)9.8821.141—85.619 0.068
Ertapenem00NANANA
 Linezolid1 (6%)12 (39%)9.8821.141—85.619 0.068
 Glycopeptides Vancomycin1 (6%)8 (26%)5.3330.599—47.4680.216
 Teicoplanin1 (6%)5 (16%)2.9170.309—27.5600.333
Invasive procedure before
 Central venous catheterization10(59%)30 (97%)21.0002.294—192.225 0.003
 Trachea cannula4(24%)10 (32%)1.5480.401—5.9710.525
 Tracheotomy5(29%)12 (39%)1.5160.426—5.3930.519
 Urinary catheter7(41%)23 (74%)4.1071.168—14.436 0.024
 stomach tube14(82%)27 (87%)1.4460.283—7.3840.656
 Intrathoracic drain0(0)4 (13%)0.6140.485—0.7760.282
 Abdominal cavity drainage-tube5(29%)15 (48%)2.2500.639—7.9230.202
 External ventricular drainage tube care0(0)1 (3%)0.6120.490—0.7651
 Liver function on admission5(35%)3 (10%)0.2570.053—1.252 0.079
 Renal function on admission7(41%)4(13%)0.2750.071—1.070 0.055
 APACHE II score on admission12.29 ± 7.329.45 ± 4.600.334

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, OR odds ratio, CI confidence interval, HIV human immunodeficiency virus, APACHE Acute Physiology and Chronic Health Evaluation

aHistory of surgery and non-invasive procedures, such as endoscopy or colonoscopy, are excluded from this category

bImmunosuppressors: Immunosuppressive drugs, immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of the immune system, including cytostatics, antibodies, drugs acting on immunophilins, etc. (https://en.wikipedia.org/wiki/Immunosuppressive_drug)

Univariate analysis of risk factors for CRKp BSI Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, OR odds ratio, CI confidence interval, HIV human immunodeficiency virus, APACHE Acute Physiology and Chronic Health Evaluation aHistory of surgery and non-invasive procedures, such as endoscopy or colonoscopy, are excluded from this category bImmunosuppressors: Immunosuppressive drugs, immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of the immune system, including cytostatics, antibodies, drugs acting on immunophilins, etc. (https://en.wikipedia.org/wiki/Immunosuppressive_drug) Variables significant at p < 0.10 in the univariate analyses were included in the multivariate analysis, and were as follows: an indwelling central venous catheter, indwelling urinary catheter, exposure to linezolid, imipenem and meropenem, and liver and kidney function at admission. In the multivariate analysis, central venous catheterization was the only independent factor for CRKp BSI. Exposure to imipenem and meropenem were likely related to CRKp BSI, but the association was not significant due to the small sample (Table 4).
Table 4

Multivariate analysis of risk factors for CRKp BSI

VariableAdjusted OR95% CI P-value
Indwelling central venous catheters14.3431.063—193.4440.045
Exposure to meropenem11.9680.756—69.7200.086
Exposure to imipenem7.2580.945—151.4970.055

Abbreviations: OR odds ratio, CI confidence interval

Multivariate analysis of risk factors for CRKp BSI Abbreviations: OR odds ratio, CI confidence interval

Risk factors for mortality of K. pneumoniae BSI patients

In univariate analyses, the mortality of K. pneumoniae BSI patients was significantly associated with the APACHE II score on the day of bacteremia, but not with CRKp. Liver failure on the day of bacteremia and trachea cannula showed a trend towards being associated with a higher mortality rate. Variables significant at p < 0.10 in the univariate analyses were included in the multivariate analysis. However, no factor was identified as being associated with the mortality of K. pneumoniae BSI patients in the multivariate analysis, likely due to the small sample size (Table 5).
Table 5

Univariate analysis of the 28-day mortality rate of K. pneumoniae BSI patients in the ICU

VariableDied (n = 21)Survived (n = 27)Univariate analysis
P OR95% CI
Sex (male, n)
Age (y) (mean ± SD)57.74 ± 16.6361.57 ± 13.690.448
APACHE II score at admission11.50 ± 5.5310.07 ± 4.950.406
APACHE II score on the day of bacteremia18.29 ± 7.3614.48 ± 6.110.031
Liver failurea at admission780.7841.1880.348—4.051
Kidney failureb at Admission470.5740.6720.168—2.694
Liver failure on the day of bacteremia1170.063.1430.933—10.584
Kidney failure on the day of bacteremia660.6141.4000.377—5.195
Co-infection14200.5750.7000.2—2.445
CRKp12(57.1%)19(70.3%)0.3420.5610.170—1.856
Diabetes mellitus5(23.8%)9(23.3%)0.3710.5560.152—2.027
Hypertension10(47.6%)14(51.9%)0.7710.8440.270—2.644
Coronary heart disease2(9.5%)2(7.4%)0.7921.3160.170—10.208
Chronic renal failure2(9.5%)4(14.8%)0.5820.6050.1—3.672
Solid organ tumor4(19%)7(25.9%)0.5740.6720.168—2.694
Surgery in the past medical history2(9.5%)6(22.2%)0.2420.3680.066—2.050
Prior healthcare-associated exposure8(38.1%)8(29.6%)0.5371.4620.437—4.889
Glucocorticoid8120.6580.7690.240—2.460
Immunosuppressor2(9.5%)1(3.7%)0.4092.7370.231—32.430
Central venous catheterization17(81%)23(85.2%)0.6960.7390.161—3.383
Trachea cannula9(42.9%)5(18.5%)0.0663.30.899—12.108
Tracheotomy6(27.3%)11(40.7%)0.3250.5450.162—1.833
Urinary catheter13(61.9%)17(16.9%)0.9400.9560.295—3.102
Abdominal cavity drainage- tube6(28.6%)14(51.9%)0.1050.3710.111—1.247
Stomach tube18(85.7%)23(85.2%)0.9591.0430.305—0.593
Intrathoracic drain04(14.8%)0.1210.5230.394—0.693
External ventricular drainage tube care1(4.7%)00.4380.4260.305—0.593

Abbreviations: OR odds ratio, CI confidence interval, CRKp carbapenem-resistant Klebsiella pneumoniae

aLiver failure was defined as a serum bilirubin level of >3 mg/dl and/or prothrombin time (PT) of <50% on day 5 after surgery or thereafter; in patients with jaundice, it was defined as an increase in the serum bilirubin level or a PT < 50% on day 5 or thereafter [53]

bKidney failure was defined as a creatinine level of ≥2 mg/dl or requirement for dialysis [33]

Univariate analysis of the 28-day mortality rate of K. pneumoniae BSI patients in the ICU Abbreviations: OR odds ratio, CI confidence interval, CRKp carbapenem-resistant Klebsiella pneumoniae aLiver failure was defined as a serum bilirubin level of >3 mg/dl and/or prothrombin time (PT) of <50% on day 5 after surgery or thereafter; in patients with jaundice, it was defined as an increase in the serum bilirubin level or a PT < 50% on day 5 or thereafter [53] bKidney failure was defined as a creatinine level of ≥2 mg/dl or requirement for dialysis [33]

Molecular characteristics of CRKp and CSKp BSI

The PFGE patterns revealed that the 33 isolates had different origins (Fig. 1). MLST revealed considerable clonal diversity; 18 sequence types (STs) were detected (Fig. 2), of which ST11 comprised the majority.
Fig. 1

Pulsed-field gel electrophoresis (PFGE) results. Pulsotypes of 33 K. pneumoniae blood isolates. The PFGE patterns revealed that the 33 isolates had different origins

Fig. 2

Multilocus sequence typing (MLST) results. Eighteen sequence types (STs) of 33 K. pneumoniae blood isolates. MLST indicated considerable clonal diversity; 18 STs were detected, of which ST11 comprised the majority

Pulsed-field gel electrophoresis (PFGE) results. Pulsotypes of 33 K. pneumoniae blood isolates. The PFGE patterns revealed that the 33 isolates had different origins Multilocus sequence typing (MLST) results. Eighteen sequence types (STs) of 33 K. pneumoniae blood isolates. MLST indicated considerable clonal diversity; 18 STs were detected, of which ST11 comprised the majority The CSKp isolates harbored the rmpA2, allS, K1, and magA virulence genes, while the CRKp isolates possessed rmpA2, magA, and K5, but not allS or K1. rmpA, K2, K20, K54, and K57 were not detected. The frequency of detection of allS and magA was higher in the CSKp group than in the CRKp group (allS p = 0.04; magA p = 0.047) (Table 6).
Table 6

Frequency rates of bacterial virulence genes in 33 isolates

VariableCSKp (n = 12)CRKp (n = 21)P
rmpA2340.686
Alls300.04
K1100.364
K5011
magA410.047
K1+ magA100.364
rmpA2 + magA100.364
alls + magA100.364
rmpA00
K200
K2000
K5400
K5700

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae

Frequency rates of bacterial virulence genes in 33 isolates Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae

Discussion

CRKp BSI is a global public health problem that has been increasing in recent times, and is responsible for considerable morbidity [20, 28, 29]. The incidence of K. pneumoniae BSIs in ICU patients exceeds that of Escherichia coli BSIs [30, 31]. The mortality rate of critical patients with K. pneumoniae BSIs in the ICU was reported to rise up to 67.6% [30]. Population-based screening for K. pneumoniae bacteremia was conducted in the Calgary Health Region (population, 1.2 million) from 2000 to 2007. Dialysis, solid-organ transplantation, chronic liver disease, and cancer were risk factors for K. pneumoniae bacteremia [10]. CRE surveillance in Michigan healthcare facilities showed that cardiovascular disease, renal failure, and diabetes mellitus were the most frequently reported comorbidities, and risk factors for CRE included surgery within the previous 90 days, recent infection or colonization with a multidrug-resistant organism, and recent exposure to antimicrobials, particularly third- or fourth-generation cephalosporins [32]. The more frequent hospital contact associated with serious comorbidities may result in exposure to, and possibly infection by, nosocomial microorganisms. Moreover, severe chronic comorbidities were more frequent among patients with CRKp BSIs, but chronic comorbidities were not risk factors for CRKp BSI [33]. Similarly, in this study, comorbidities were not independent risk factors for CRKp BSI. Glucocorticoids and immunosuppressors were not independent risk factors for CRKp BSI; however, previous studies reported different results. In one study, only prior carbapenem administration (p = 0.003), was significantly associated with CRKp infection, and another study revealed that the type of antibiotic used before infection—such as third-generation cephalosporins, macrolides and quinolones—was an independent risk factor for CRKp (p < 0.05) [34, 35]. Indeed, prior use of macrolides and antibiotic exposure for ≥14 days were the only factors independently associated with nosocomial CRKp bacteremia [33]. In another case-case control study, exposure to quinolones was not associated with CRKp infection, and colonization by CRKp and use of carbapenems were risk factors for infection with CRKp [36]. However, in our study, no antibiotic was a risk factor for CRKp BSI. Different in definitions, the duration of exposure to antibiotics, or different drug-treatment populations among these studies may account for the divergent findings. In terms of invasive procedures, only an indwelling central venous catheter and urinary catheter were associated with CRKp BSI in univariate analyses. In the multivariate analysis, an indwelling central venous catheter was the only factor independently associated with CRKp BSI, partly consisted with the past studies [37, 38]. However, previous studies indicated that other variables, such as mechanical ventilation and a nasogastric tube, were related to CRKp BSI [38, 39, 40]. Liver and kidney function indices at admission were higher in the CSKp group than in the CRKp group in this study, similar to some previous studies [41, 42]. However, reduced liver and kidney function was not associated with CRKp BSIs. To improve outcomes, and where there is a need to avoid unnecessary antibiotics so as to reduce CRKp emergence, greater efforts should be made to ensure that initial appropriate antibiotic therapy is delivered to critically ill infected patients, and antibiotic de-escalation should be practiced to avoid unnecessary antibiotic exposure [43]. Moreover, control of the infection source is important for reducing the incidence of BSI. Central line (CL)-associated BSIs in ICUs result in increased morbidity and mortality, and are largely preventable; thus, preventive measures for catheter-related infection are important. Such measures can be applied at central line insertion and maintenance. For example, use of maximal sterile barrier precautions and/or avoiding the femoral vein were applied to reduce the risk of central venous catheter-related bloodstream infection. Moreover, use of central lines should be reduced wherever possible, such as by daily assessment of the need for a CL and timely removal of an unnecessary CL [44]. Infection-related mortality involves a number of factors, including host defense, virulence of the pathogen, source location and control, and the efficacy of available antimicrobials. A recent meta-analysis showed that patients with CRKp had a significantly higher mortality rate than those with CSKp (42.14 vs. 21.12, p < 0.001) [45]; this suggests that antimicrobial resistance is related to mortality. However, severe infections are not necessarily caused by drug-resistant bacteria, i.e., antimicrobial resistance is not linked with infection-induced organ dysfunction or failure, or with mortality, in critically ill patients. Therefore, the difference in clinical features and risk factors between CSKp and CRKp BSIs is intriguing. In our study, the CSKp BSI patients had more severe clinical characteristics, such as higher APACHE II scores and lower alanine transaminase (AST) levels. Indeed, the serum creatinine level at the time of the positive culture was significantly higher in the CSKp group than in the CRKp group. However, CSKp BIS patients had only a trend towards a higher mortality rate. Therefore, although CS-Kp infection can lead to worse clinical symptoms, the mortality rate is similar between the two groups, despite there being fewer therapeutic options for CRKp BSI. The risk factors for mortality due to CSKp and CRKp infection were evaluated in this study. The mortality of K. pneumoniae BSI patients was associated with a higher APACHE II score, liver failure, and trachea cannula on the day of bacteremia, but not with carbapenem resistance. In another study, multivariate analyses revealed that carbapenem resistance was not a risk factor for mortality due to K. pneumoniae bacteremia [33]. The mortality rate of CRKp patients was significantly higher than that of CSKp patients in that study, which contradicts our findings and those of a study conducted in Israel in 2012 [46]. The risk factors for mortality due to K. pneumoniae BSI vary among studies, and include bedridden status, chronic liver disease, Charlson comorbidity index ≥5, mechanical ventilation, hemodialysis [33], and Pitt bacteremia score [46]. PFGE and MLST revealed that the isolates had considerable clonality; the 33 isolates were of different origins. No suspected outbreaks occurred during the study period. We assessed the frequency of 10 virulence genes in the CSKp and CRKp BSI isolates. magA is involved in the production of the K1 capsule, which is an important virulence factor [47]. A previous study confirmed local emergence of K. pneumoniae invasive syndrome and implicated magA and rmpA in its pathogenesis [48]. A number of putative virulence factors, including magA and rmpA, are associated with hypermucoviscous K. pneumoniae (hvKP), which can cause serious infections [49, 50]. Alarmingly, multidrug-resistant, including carbapenem-resistant hvKP isolates have emerged [23, 51, 52]; thus, we assessed the frequency rates of various virulence genes in the CRKp and CSKp groups. The frequency rates of allS and magA were higher in the CSKp group than in the CRKp group, despite the small number of subjects. Therefore, further studies of virulence genes, possibly using whole-genome sequencing (which is becoming less costly and more rapid) and involving larger populations, are warranted. Our study had several limitations. First, relatively few patients were enrolled, which hampered the multivariate analysis and ability to draw firm conclusions. Second, some K. pneumoniae isolates were not stored. Third, the therapeutic regimen for K. pneumoniae BSI was not taken into consideration. Fourth, in the ICU setting, a heterogeneous population can limit the statistical analysis. Fifth, the role of the immune system was not analyzed. Despite these limitations, however, we identified several differences between the CRKp and CSKp groups, and explored the impact of carbapenem resistance and bacterial virulence genes on the outcomes of patients with K. pneumoniae BSIs.These data can lay the groundwork for future research in this field.

Conclusions

An indwelling central venous catheter is a risk factor for CRKp BIS. Liver and kidney function at admission were lower in the CSKp group than in the CRKp group in this study. The mortality rate and frequency of bacterial virulence genes were similar between the CSKp and CRKp groups. Mortality due to K. pneumoniae BSI was not related to carbapenem resistance in univariate analysis. Further study is required to verify the correlation between CRKp-mortality mortality and the virulence genes of K. pneumoniae isolates.
  47 in total

1.  Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Jason C Gallagher; Safia Kuriakose; Kevin Haynes; Peter Axelrod
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  Prevalence and drug resistance characteristics of carbapenem-resistant Enterobacteriaceae in Hangzhou, China.

Authors:  Yan Yang; Jian Chen; Di Lin; Xujian Xu; Jun Cheng; Changgui Sun
Journal:  Front Med       Date:  2017-07-08       Impact factor: 4.592

3.  Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.

Authors:  Pamela Ny; Paul Nieberg; Annie Wong-Beringer
Journal:  Am J Infect Control       Date:  2015-07-17       Impact factor: 2.918

4.  Survey of Klebsiella pneumoniae bacteraemia in two South Australian hospitals and detection of hypermucoviscous phenotype and magA/rmpA genotypes in K . pneumoniae isolates.

Authors:  Lisa Chang; Ivan Bastian; Morgyn Warner
Journal:  Infection       Date:  2012-12-08       Impact factor: 3.553

5.  Optimization of computer software settings improves accuracy of pulsed-field gel electrophoresis macrorestriction fragment pattern analysis.

Authors:  William M Duck; Christine D Steward; Shailen N Banerjee; John E McGowan; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.

Authors:  Enrico Maria Trecarichi; Livio Pagano; Bruno Martino; Anna Candoni; Roberta Di Blasi; Gianpaolo Nadali; Luana Fianchi; Mario Delia; Simona Sica; Vincenzo Perriello; Alessandro Busca; Franco Aversa; Rosa Fanci; Lorella Melillo; Federica Lessi; Maria Ilaria Del Principe; Chiara Cattaneo; Mario Tumbarello
Journal:  Am J Hematol       Date:  2016-07-29       Impact factor: 10.047

7.  Clinical Characteristics of Carbapenem-resistant Klebsiella pneumoniae Infections in Ill and Colonized Children in Colombia.

Authors:  Alejandro Díaz; Diana Cristina Ortiz; Mónica Trujillo; Carlos Garcés; Fabian Jaimes; Andrea Victoria Restrepo
Journal:  Pediatr Infect Dis J       Date:  2016-03       Impact factor: 2.129

8.  Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Authors:  Mitchell J Schwaber; Shiri Klarfeld-Lidji; Shiri Navon-Venezia; David Schwartz; Azita Leavitt; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

Review 9.  Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.

Authors:  Gláucia F Cota; Marcos R de Sousa; Tatiani Oliveira Fereguetti; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2013-05-02

10.  Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey.

Authors:  Cristina Valencia; Naïma Hammami; Antonella Agodi; Alain Lepape; Eduardo Palencia Herrejon; Stijn Blot; Jean-Louis Vincent; Marie-Laurence Lambert
Journal:  Antimicrob Resist Infect Control       Date:  2016-11-22       Impact factor: 4.887

View more
  9 in total

1.  Carbapenem-Resistant Klebsiella pneumoniae in Southwest China: Molecular Characteristics and Risk Factors Caused by KPC and NDM Producers.

Authors:  Zhaoyinqian Li; Zixuan Ding; Jia Yang; Yao Liu; Xinrui Jin; Jingling Xie; Tingting Li; Yinhuan Ding; Zhangrui Zeng; Jinbo Liu
Journal:  Infect Drug Resist       Date:  2021-08-13       Impact factor: 4.003

2.  Outcomes and Risk Factors of Bloodstream Infections Caused by Carbapenem-Resistant and Non-Carbapenem-Resistant Klebsiella pneumoniae in China.

Authors:  Xiaoxue Liang; Ping Chen; Baoguo Deng; Feng-Hui Sun; Yongqiang Yang; Yanxian Yang; Ruowen He; Mingyang Qin; Yiping Wu; Fan Yang; Guo-Bao Tian; Min Dai
Journal:  Infect Drug Resist       Date:  2022-06-17       Impact factor: 4.177

3.  High prevalence of extended-spectrum beta-lactamase-producing Gram-negative pathogens from patients attending Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Amhara region.

Authors:  Feleke Moges; Setegn Eshetie; Wondwossen Abebe; Feleke Mekonnen; Mulat Dagnew; Abyot Endale; Azanaw Amare; Tigist Feleke; Mucheye Gizachew; Moges Tiruneh
Journal:  PLoS One       Date:  2019-04-15       Impact factor: 3.240

4.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis.

Authors:  Wei-Min Zhu; Zhe Yuan; Hong-Yu Zhou
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-31       Impact factor: 4.887

5.  Analysis of the Clinical Effect of Combined Drug Susceptibility to Guide Medication for Carbapenem-Resistant Klebsiella pneumoniae Patients Based on the Kirby-Bauer Disk Diffusion Method.

Authors:  Huijuan Yao; Jingxian Liu; Xueyan Jiang; Feng Chen; Xiaotong Lu; Jian Zhang
Journal:  Infect Drug Resist       Date:  2021-01-12       Impact factor: 4.003

6.  Emergence of Hypervirulent ST11-K64 Klebsiella pneumoniae Poses a Serious Clinical Threat in Older Patients.

Authors:  Tian Wei; Chengyun Zou; Jie Qin; Jianmin Tao; Li Yan; Jiangjun Wang; Hong Du; Fang Shen; Yanqin Zhao; Haiying Wang
Journal:  Front Public Health       Date:  2022-03-04

7.  No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.

Authors:  Shi Thong Heng; Swaine L Chen; Joshua G X Wong; David C Lye; Tat Ming Ng
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

8.  Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections and Outcomes.

Authors:  Youhua Yuan; Junjie Wang; Zonghui Yao; Bing Ma; Yi Li; Wenjuan Yan; Shanmei Wang; Qiong Ma; Jiangfeng Zhang; Junhong Xu; Li Li; Yuming Wang; Enguo Fan
Journal:  Infect Drug Resist       Date:  2020-01-22       Impact factor: 4.003

9.  Risk Factors Affecting Clinical Outcome in Patients with Carbapenem-Resistant K. pneumoniae: A Retrospective Study.

Authors:  Gefei He; Juanjuan Huang; Shiqiong Huang; Ji Sun; Yulv Zhou; Hong Tan; Hui Shen; Zhuan Li; Jiyang Liu
Journal:  Med Sci Monit       Date:  2020-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.